An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
InVivo Therapeutics Announces Participation at Upcoming H.C. Wainwright 24th Annual Global Investment Conference
Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), focusing on spinal cord injury treatment, announced CEO Richard Toselli will present at the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022. The company's management will engage in virtual one-on-one meetings with registered investors. Dr. Toselli's presentation will be accessible via webcast on the company's website starting September 12, 2022, at 7:00 am ET.
Positive
Participation in H.C. Wainwright Annual Global Investment Conference may enhance investor relations and visibility.
Webcast availability allows broader audience access to the company's updates.
Negative
None.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--
InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries, today announced that Richard Toselli, M.D., President and Chief Executive Officer, will present at the upcoming H.C. Wainwright 24th Annual Global Investment Conference, which runs from September 12 – 14, 2022. Dr. Toselli and company management will also be available to participate in virtual one-on-one meetings with registered investors attending the conference.
A webcast of Dr. Toselli’s presentation will be available on the Investor Relations - Events section of the company website at https://investors.invivotherapeutics.com/events, beginning September 12, 2022 at 7:00 am ET.
About InVivo Therapeutics
InVivo Therapeutics Holdings Corp. is a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries. The company was founded in 2005 with proprietary technology co-invented by Robert Langer, Sc.D., Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who then was at Boston Children’s Hospital and who now is affiliated with Massachusetts General Hospital. The publicly traded company is headquartered in Cambridge, MA. For more details, visit www.invivotherapeutics.com.
